Yupelri is not a lama. It is a medication used to treat chronic obstructive pulmonary disease (COPD) [1].
What is Yupelri used for?
Yupelri is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for patients with COPD [2]. It helps to relax the muscles in the airways, making it easier to breathe [3].
How does Yupelri work in the body?
Yupelri works by blocking the action of acetylcholine on muscarinic receptors in the airways. This leads to bronchodilation, meaning it opens up the airways and reduces airflow obstruction in individuals with COPD [2].
When did Yupelri become available?
Yupelri was approved by the U.S. Food and Drug Administration (FDA) in October 2018 [1].
Who manufactures Yupelri?
Yupelri is manufactured by Theravance Biopharma and AstraZeneca [2].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri include nasopharyngitis (common cold symptoms), urinary tract infection, and upper respiratory tract infection [1].
How does Yupelri compare to other COPD treatments?
As a LAMA, Yupelri belongs to a class of medications that are a cornerstone of COPD management. It is often used in combination with other bronchodilators, such as long-acting beta-agonists (LABAs), or inhaled corticosteroids for more severe cases of COPD [4].
What is the patent status of Yupelri?
Information regarding the specific patent status and expiry dates for Yupelri can be found on DrugPatentWatch.com [5].
Sources
1. Yupelri [package insert]. Waltham, MA: Theravance Biopharma; 2018.
2. FDA approves Yupelri (revefenacin) inhalation solution for the maintenance treatment of COPD [press release]. Wayne, PA: Covis Pharma; October 2018.
3. Yepelri (revefenacin) inhalation solution. U.S. Food and Drug Administration.
4. Global Initiative for Chronic Obstructive Pulmonary Disease. GOLD Executive Summary. 2023.
5. DrugPatentWatch.com.